Tags

Type your tag names separated by a space and hit enter

Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
Drugs Exp Clin Res. 1999; 25(1):29-36.DE

Abstract

The authors evaluated the efficacy of propionyl-l-carnitine, a drug able to reduce peripheral resistance and protect the cells against oxidative stress damage, in patients affected by peripheral arterial obliterative disease at class II of Fontaine. The study was performed on 22 patients according to a double-blind, randomized design in parallel with placebo. The drug was administered at a dosage of 1 g three times a day orally for 90 days. At recruitment and at the end of the study all patients underwent physical examination, treadmill test, doppler C.W. of the lower limbs, ankle/brachial index, dosage of tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), hematocrit, hematic filtration, and viscosity. In the group treated with propionyl-l-carnitine a statistically significant increase of claudication distance, blood flow velocity, PAI-1 activity and red blood cell deformity was observed. These data suggest the usefulness of propionyl-l-carnitine in the treatment of patients affected by peripheral arterial obliterative disease.

Authors+Show Affiliations

Catholic University of the Sacred Heart, Chair of Internal Medicine, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

10337502

Citation

Dal Lago, A, et al. "Effects of propionyl-L-carnitine On Peripheral Arterial Obliterative Disease of the Lower Limbs: a Double-blind Clinical Trial." Drugs Under Experimental and Clinical Research, vol. 25, no. 1, 1999, pp. 29-36.
Dal Lago A, De Martini D, Flore R, et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Exp Clin Res. 1999;25(1):29-36.
Dal Lago, A., De Martini, D., Flore, R., Gaetani, E., Gasbarrini, A., Gerardino, L., Pola, R., Santoliquido, A., Serricchio, M., Tondi, P., & Nolfe, G. (1999). Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Under Experimental and Clinical Research, 25(1), 29-36.
Dal Lago A, et al. Effects of propionyl-L-carnitine On Peripheral Arterial Obliterative Disease of the Lower Limbs: a Double-blind Clinical Trial. Drugs Exp Clin Res. 1999;25(1):29-36. PubMed PMID: 10337502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. AU - Dal Lago,A, AU - De Martini,D, AU - Flore,R, AU - Gaetani,E, AU - Gasbarrini,A, AU - Gerardino,L, AU - Pola,R, AU - Santoliquido,A, AU - Serricchio,M, AU - Tondi,P, AU - Nolfe,G, PY - 1999/5/25/pubmed PY - 1999/5/25/medline PY - 1999/5/25/entrez SP - 29 EP - 36 JF - Drugs under experimental and clinical research JO - Drugs Exp Clin Res VL - 25 IS - 1 N2 - The authors evaluated the efficacy of propionyl-l-carnitine, a drug able to reduce peripheral resistance and protect the cells against oxidative stress damage, in patients affected by peripheral arterial obliterative disease at class II of Fontaine. The study was performed on 22 patients according to a double-blind, randomized design in parallel with placebo. The drug was administered at a dosage of 1 g three times a day orally for 90 days. At recruitment and at the end of the study all patients underwent physical examination, treadmill test, doppler C.W. of the lower limbs, ankle/brachial index, dosage of tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), hematocrit, hematic filtration, and viscosity. In the group treated with propionyl-l-carnitine a statistically significant increase of claudication distance, blood flow velocity, PAI-1 activity and red blood cell deformity was observed. These data suggest the usefulness of propionyl-l-carnitine in the treatment of patients affected by peripheral arterial obliterative disease. SN - 0378-6501 UR - https://www.unboundmedicine.com/medline/citation/10337502/Effects_of_propionyl_L_carnitine_on_peripheral_arterial_obliterative_disease_of_the_lower_limbs:_a_double_blind_clinical_trial_ DB - PRIME DP - Unbound Medicine ER -